Kling Biotherapeutics to Present Key Applications for its Primary B-Cell Immortalization, Screening and Antibody Optimization Platform Technologies at PEGS Europe
Kling Biotherapeutics to Present Key Applications for its Primary B-Cell Immortalization, Screening and Antibody Optimization Platform Technologies at PEGS Europe
- Kling-Select is a uniquely promising approach to identifying novel targets and therapeutic antibodies from human and animal sources
- Kling-Evolve enables highly rapid selection of effective neutralizing antibodies against viral escape variants
Amsterdam, NLD – 31 October 2024 – Kling Biotherapeutics (“Kling” or “the Company”), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announces that it will be presenting findings on its proprietary primary B-cell selection and evolution platform technologies, Kling-Select and Kling-Evolve at the Annual Protein & Antibody Engineering Summit (PEGS) Europe, held in Barcelona, Spain from 5-7 November 2024.
